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Hydrophobic pcptides were isolated from the phospholipid fraction of human bile, plasma and spleen by exclusion chromatography in organic 
solvents. From plasma, the activation peptide of CL protcasc inhibitor was recovered, from spleen the activation peptide of a,-antitrypsin, and 
from bile, both these pptides, as well as a fragment generated by proteolytic leavage ofa,-antitrypsin six residues N-terminal of the PI-PI ’ peptide 
bond. Cleavages in this region inactivate antiproteases but have previously not been reported to occur in vivo. These peptides in human bile may 
reflect physiological actions in regulation of antiproteolytic activity or bile secretion processes, and/or be of importance for the physicochemical 
state of cholcstcrol, phospholipids and bile acids in bile. 
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1. INTRODUCTION was isolated by liquid-gel chromatography on Lipidexm5000 in the 
solvent system methanol/ethylene chloride (4:l. v/v) [I I]. 
During the complex formation between a serpin 
(serine proteasc inhibitor) and its target protease. the 
protease cleaves a specific peptide bond, the Pl-PI’ 
bond, of the serpin active site. This cleavage liberates 
the C-terminal activation peptide, consisting of about 
35 residues, from the antiprotease. The lo-residue seg- 
ment of the serpin preceding the PI-PI bond is exposed 
in the tertiary structure [l,:!] and susceptible to proteo- 
lytic cleavage (cf. [3]). Cleavage within this segment in- 
stead of at the PI-PI ’ bond inactivates the antiprotease 
and liberates a correspondingly onger inactivation pep- 
tide. Such cleavages can be mediated by endogenous 
serpin target proteases [&8], and by non-target 
proteases from both venom and bacterial toxins [7-g]. 
This mechanism has therefore been proposed to be in- 
volved in bacterial pathogenicity [7], and in inflamma- 
tion [3,4], but an in vivo physiological production of 
these fragments has, to our knowledge, not been 
reported. We now identify such an inactivation peptide 
from or,-antitrypsin, recovered in the phospholipid frac- 
tion of human bile. 
Plasma and bile were mixed with 4 vols. of chloroform/methanol 
(2:l v/v). The lower phase was filtered and the phospholipids were 
isolated as described above. 
2.2. Proreirl p~rr~Qkoriott 
Peptides in the phospholipid fraction of spleen, plasma and bile 
were isolated by chromatography on Sephadex LH-60 in chloroform/ 
methanol (1: I, v/v). containing 5% 0. I M HCI [I I] and pooled into two 
fractions (corresponding to positions of elution of the lipopcptidcs 
SP-B and SP-C previously isolated from pulmonary phospholipids 
[I I]). Aliquots of both pools from each source were reduced, treated 
with iodo[“C]acctatc and separated from excess reagents [I21. Analy- 
sis of the peptidcs from the three sources howed ifferent sequences, 
but in cdch case the two pools gave identical results except for separate 
recoveries (more in the xc;nd pool, cf. section 3. I .). 
2.3. Srrucrtrrfri artrrlysis 
Acid hydrolysis for amino acid composition was ptrformed in 6 M 
HCl/O,5% phenol at I 10°C for 24 h, or at 1 50bC for 72 h, Scqucnccr 
analyses were carried out with an ABI 470A gas-phase instrument, 
equipped with an on-line IZOA Analyzer for detection of liberated 
phenylthiohydantoin derivatives. The amino acid sequences obtained 
were identified by searching the Protein Identification Resource data 
base using the FASTA program. Plasma dcsorption mass spec- 
trometry was performed as described [13]. 
2. MATERIALS A.ND METHODS 
9. I, Phospholipid isolution 
Spleen tissue was homogenized in chloroform/methanol (2:I, v/v). 
After filtration. 0.2 vola. of 0.1 M NaCl in water was added [IO]. The 
lower phase was evaporated to dryness and the phospholipid fraction 
3. RESULTS AND DlSCUSSION 
3.1. identificcttion of antiprotcase fragmwd 
Cwespondrnce uddress: J. Johansson. Department of Chemistry I. 
Karolinska Institutet, S-104 01 Stockholm, Sweden. Fax: (45) 
8337462. 
Peptides in the phospholipid fraction of bile, plasma 
and spleen were submitted to Sephadex LM-60 chroma- 
tography, and the eluates were divided into two pools 
(cf. section 2.2.j. In each case, the major part of the 
peptide material was recovered in the second pool, but 
the two pools gave identical sequence results. The as- 
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signments, based on both sequence analysis and total 
compositions after hydrolysis, are summarized in Table 
I. The sequence of the peptide from plasma was identi- 
cal to that of Cl protease inhibitor activation peptide 
([14]; monito!:ed for 27 residues), and that of the peptide 
from spleen was identical to a,-antitrypsin activation 
peptide ([ 151; monitored for 13 residues). In bile, both 
the Cl protease inhibitor activation peptide (monitored 
for 18 residues) and the ol,-antitrypsin activation pep 
tide (monitored for 20 residues) were recovered. In addi- 
tion, a third peptide starting six residues N-terminal of 
the Pl-PI’ bond of a,-antitrypsin was found in bile. 
This sequence was monitored for 17 residues and gave 
an extensive overlap beyond the Pl-Pl’ bond, which 
was therefore stablished to remain intact in this pep- 
tide. 
From each of the three sources, the peptides in Table 
I were the only major fragments detected. Thus, the 
antiprotease fragments are the main peptides recovered 
from the phospholipid fractions of human plasma, 
spleen and bile. No radioactivity was incorporated into 
the protein fractions after [‘Qcarboxymethylation, 
further indicating that the Cys-free activation and in- 
activation peptides are the only proteins present in 
appreciable amounts. 
The a,-antitrypsin activation peptide was subjected 
to plasma desorption mass spectrometry. Ions at m/z 
4172, 2085 and 1390 were obtained, corresponding to 
molecular ions with one, two and three charges, respec- 
tively. These values are in good agreement with the 
calculated molecular mass (4130) of the intact activa- 
tion peptide, provided that the ions observed are mainly 
sodium and potassium ion adducts, as for other pep- 
tides analyzed with plasma desorption mass spec- 
trometry [13]. This shows that the a,-antitrypsin activa- 
tion peptide had not undergone proteolytic processing. 
3.2. Presence of nnriprorwse.frugments in bile 
Protein constitutes a substantial part of the solutes in 
bile [Ia] but fragments of antiproteases have, to our 
knowledge, not previously been detected in bile. A par- 
tially characterized anionic protein fraction previously 
purified from bile [17] is unlikely to have contained 
antlprotease fragments since these have an excess of 
positive charges and amino acid compositions different 
from those then obtained from an anionic bile protein 
fraction [ 173. 
3.3. in viva producrion oj’ both inactivutiort and acrivu- 
tion peptides 
The a,-antitrypsin peptide with a starting point six 
residues N-terminal of the Pl-Pl’ bond is considered to 
be a true in viva product for three reasons. First, it was 
found in abo-ut he same amount as the nctivetior? pep- 
tides. Second, its PI-P1 ’ bond is not cleaved, and third, 
no evidence of unspecific proteolytic processing within 
the activation peptides was obtained. The finding of this 
Table I 
Summary of peptidcs identified by sequence analysis of the hydro- 
phobic peptidc fractions from human plasma. spleen and bile 
Source Peptides idcntitied Recovery 
(mtikg) 
Plasma 
Spleen 
Cl protease inhibitor activation 
peptidc (Thr’“‘-AlaW) 
o,-Antitrypsin activation 
peptidc (SerD3-Lys4”‘) 
0.2 
30 
Bile Cl urotcase inhibitor 1 
aciivation pptidc 
a,-Antiirypsin 
activation peptidc 
a,-Antitrypsin inactivation 
pcptide (Leu”‘-Lys~‘8) 
t 
0.2 
Start and end pointsof the pcptides identified are indicated by residues 
and positional numbers, referring to intact scrpin amino acid sc- 
quenccs for Cl protcase inhibitor 1141 and o,-antitrypsin [IS]. Re- 
coveries are given as mg of total hydrophobic peptides isolated per kg 
starting material. In bile, the three fragments were recovered in 
roughly equimolar amounts. 
peptide in human bile may indicate that cleavage within 
the protease sensitive region constitutes a mode of 
regulation of serpins during normal physiology. Thus, 
a,-antitrypsin has be.,. . am round to be insensitive to treat- 
ment with elastase from human neutrophils [4], but is 
cleaved by proteases from Staphylococcus aureus [q and 
elastase from Psrudontotzas aeruginosu [ l8] and macro- 
phages [6]. If the inactivation peptide in human bile is 
generated by its natural target protease, elastase, this 
would have a greater possibility to cleave within the 
exposed region of ol,-antitrypsin vivo than previously 
detected in vitro. Irrespective of the mode of produc- 
tion, the presence of the inactivation peptide in vivo 
may reflect a physiological balance of the proteolytic/ 
antiproteolytic activities in the system. 
No a,-antitrypsin fragments were found in plasma 
(Table I) although the normal plasma concentration of 
rr,-antitrypsin isabout 5 times that of Cl pro+.ease inhib- 
itor. This raises the possibility of local production of the 
fragments in the liver and/or bile ducts. Thus, the hy- 
drophobic peplide fragments recovered ipt ‘?!ile may be 
of importance for specific association with bile lipid 
components. This appears interesting for two reasons. 
First, cholesterol and phospholipids eem to be secreted 
as vesicles from the hepatocytes aided by the secretion 
of bile acids [19-211. Although there is no established 
dependence on antiprotease activities in this process, 
patients with a,-antitrypsin deficiency after. suffer from 
intrahepatic cholestasis (see [22]?. Thus. the excretion of 
the peptides in bile could reflect a function of anti- 
proteases or antiprotcase fragments in targetting or 
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secretion of cholesterol/phospholipid vesicles into bile. 
Second, cholesterol and phospholipids occur in bile as 
vesicles and other aggregates or as mixed micelles with 
bile acids [23], and the form in which cholesterol occurs 
and interacts with biliary proteins influences the nuclea- 
tion process in gallstone formation [X-26]. The hydro- 
phobicity of the peptides identified and their association 
with phospholipids might indicate that they are of im- 
portance for the distribution of cholesterol between dif- 
ferent physical forms. Thus, the peptides may influence 
the development of diseases uch as intrahepatic ho- 
lestasis and gallstone formation. 
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